Oppenheimer Assumes Allogene Therapeutics at Outperform, Lowers Price Target of $11
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Matthew Biegler assumes coverage of Allogene Therapeutics (NASDAQ:ALLO) with an Outperform rating but lowers the price target to $11.
August 08, 2024 | 2:17 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Oppenheimer's analyst Matthew Biegler assumes coverage of Allogene Therapeutics with an Outperform rating, but lowers the price target to $11.
The Outperform rating suggests a positive outlook, but the lowered price target indicates some caution. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100